O
EVH icon

OrbiMed’s Evolent Health EVH Stock Holding History

OrbiMed’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-258,400
Closed -$7.31M – 125
2024
Q3 		$7.31M Buy
+258,400
New +$6.66M 0.13% 84
2021
Q4 		– Sell
-250,000
Closed -$7.75M – 162
2021
Q3 		$7.75M Buy
+250,000
New +$6M 0.09% 141

Other funds holding EVH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

OrbiMed's EVH Position: Q4 2024 in Review

OrbiMed sold out of Evolent Health (EVH) in Q4 2024, closing a stake of 1,665,115 shares — an estimated $47.1M sold.

OrbiMed first reported a position in EVH in Q3 2021 and held it in 13 quarters. The position peaked at $94M in Q1 2023. 240 funds tracked by Wall St. Rank hold EVH as of Q4 2024.

  • OrbiMed reported no remaining Evolent Health position as of Q4 2024 after selling out during the quarter.
  • OrbiMed sold 1,665,115 Evolent Health shares in Q4 2024, an estimated $47.1M.
  • OrbiMed first reported a position in Evolent Health in Q3 2021 and held it in 13 quarters.
  • OrbiMed's Evolent Health position peaked at $94M in Q1 2023.
  • 240 funds tracked by Wall St. Rank held Evolent Health as of Q4 2024.

Based on OrbiMed's 13F filing for Q4 2024, filed 14 Feb 2025.